全球侵襲性真菌感染市場：按分子類別、感染類型、地區 - 考慮到 COVID-19 影響的規模和趨勢，預測至 2028 年

全球侵襲性真菌感染市場預計到 2022 年將達到 71.3 億美元，到 2028 年將達到 90 億美元。 預計在 2023 年至 2028 年的預測期內，複合年增長率將達到 3.96%。 免疫功能低下的人數增加，公共和私人組織為提高對各種真菌感染的認識而付出的努力正在推動市場的增長。

本報告研究了全球侵襲性真菌感染市場，並提供了全面的信息，包括市場動態、市場分析和公司概況。

內容

第 1 章執行摘要

第二章介紹

• 侵襲性真菌感染：概述
  • 侵襲性真菌感染的定義
• 侵襲性真菌感染的分類：概述
  • 侵襲性真菌感染的分類

第三章全球市場分析

• 全球侵襲性真菌感染市場：分析
  • 全球侵襲性真菌感染市場：概覽
  • 全球侵襲性真菌感染市場：按價值
  • 全球侵襲性真菌感染市場（唑類、棘白菌素、烯丙胺/嘧啶、多烯類、其他）：按分子類別
  • 全球侵襲性真菌感染市場：按傳染病類型（念珠菌、曲霉菌、隱球菌等）分類
  • 全球侵襲性真菌感染市場：按地區（北美、歐洲、亞太地區、其他）
• 全球侵襲性真菌感染市場：分子類別分析
  • 按分子類別劃分的全球侵襲性真菌感染市場：概覽
  • 全球唑類侵襲性真菌感染市場：按價值
  • 全球棘白菌素侵襲性真菌感染市場：按價值
  • 全球烯丙胺/嘧啶侵襲性真菌感染市場：按價值
  • 全球多烯侵入性真菌感染市場：按價值
  • 全球其他侵入性真菌感染市場：按價值
• 全球侵襲性真菌感染市場：感染類型分析
  • 全球侵襲性真菌感染市場：概覽：按傳染病類型分類
  • 全球念珠菌侵襲性真菌感染市場：按價值
  • 全球曲霉屬侵襲性真菌感染市場：按價值
  • 全球隱球菌侵襲性真菌感染市場：按價值
  • 全球其他侵入性真菌感染市場：按價值

第四章區域市場分析

• 北美侵襲性真菌感染市場：分析
• 歐洲侵襲性真菌感染市場：分析
• 亞太地區侵襲性真菌感染市場：分析
• 其他侵入性真菌感染市場：分析

第 5 章 COVID-19 的影響

第 6 章市場動態

• 推動增長的因素
  • 威脅生命的侵襲性真菌感染增加
  • 快速城市化
  • 老年人口
  • 醫療費用增加
  • 增加政府支持
  • 抗真菌藥物開發進展
  • 生活方式的改變和環境因素
• 任務
  • 高副作用和使用常規藥物
  • 複雜且不斷進化的真菌病原體
• 市場趨勢
  • 在疫苗和藥物設計中使用 AI
  • 增加研發活動
  • 診斷技術的進步
  • 在先進的抗真菌製劑中更多地使用納米技術

第七章競爭格局

• 全球侵襲性真菌感染公司的市場份額
• 全球侵襲性真菌感染市場公司：主要比較
• 全球侵襲性真菌感染市場的公司：產品管線

第八章公司簡介

• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Pfizer Inc.
• Cidara Therapeutics, Inc.
• Astellas Pharma Inc.
• Gilead Sciences, Inc.
• Novo Nordisk A/S (Xellia Pharmaceuticals)
• Biosergen AB
• Matinas BioPharma Holdings, Inc.
• Pulmocide Ltd.
• F2G Ltd.

Invasive fungal infections (IFIs) are serious and potentially life-threatening infections caused by fungi that invade deep tissues, organs, or the bloodstream of the human body. These infections can occur in individuals with weakened immune systems, such as those undergoing chemotherapy or organ transplant, or individuals with certain medical conditions such as diabetes or HIV/AIDS. There are hundreds of thousands of different species of fungi, about a hundred of which can infect humans, but a limited number are lethal. According to a compilation by the Journal of Fungi (JOF), the prevalence exceeds 1 billion globally, where any variant of fungal infection has been identified. These are distributed among different fungal strains that are more or less severe for the infected person. The collective name for the most severe infections is invasive (systemic). The most common types of invasive fungal infections are candidiasis, aspergillosis, and cryptococcosis. The global invasive fungal infections market was valued at US$US$7.13 billion in 2022 and is expected to be worth US$9.00 billion in 2028.

The market value is expected to grow at a CAGR of 3.96% during the forecast period of 2023-2028. The number of immunocompromised persons at high risk for fungal infections is rising globally (some 3% of the population). For these patients, high mortality rates when infected is a severe concern. Therefore, the need for more potent and safer antifungals is clear. Several promising drug candidates are now in the pipeline for the treatment of invasive fungal infections. Furthermore, an increase in initiatives by public and private organizations to raise awareness about a variety of fungal infections is expected to expand the market for antifungal drugs.

Market Segmentation Analysis:

By Molecule Class: The report provides the bifurcation of the market into five segments based on the molecule class: Azoles, Echinocandins, Allylamines/Pyrimidines, Polyenes and Others. The Azoles molecule class segment dominated the market in 2022 with leading therapeutic agents such as Noxafil, Vfend, Diflucan, and Cresemba. Azoles' market dominance can be attributed to their broad-spectrum activity. By inhibiting fungal enzymes, these agents aid in fungistatic activity. Azoles are antifungal medications that are used to treat candidemia, blastomycosis, systemic candidiasis, and ocular fungal infections. Azoles, which are divided into triazoles and imidazoles, are also used to treat systemic fungal infections.

By Infection Type: The report further provides the segmentation based on the infection type: Candidiasis, Aspergillosis, Cryptococcus and Others. Candidiasis emerged as a prominent segment, accounting for a major share in the global market. Candidiasis is caused by a type of fungus called Candida. Candida infections settle in the bloodstream and bigger organs, especially in people with compromised immune systems, such as those with diabetes or HIV. According to the CDC, the incidence (rate of new infections) of invasive candidiasis in the US is approximately 9 per 100,000 people, or approximately 25,000. In-hospital all-cause mortality is estimated to be around 25%. Risk factors for developing invasive candidiasis include prolonged use of antibiotics, invasive procedures, and immunosuppression. The increasing use of broad-spectrum antibiotics, the aging population, and the growing prevalence of immunocompromised patients are driving the growth of invasive candidiasis.

By Region: The report provides insight into the invasive fungal infections market based on the geographical operations, namely North America, Europe, Asia Pacific, and ROW. Fungal infections are more prevalent in developing countries in terms of overall prevalence. At the same time, sales of drugs related to treatment are dominated by Europe and the US.

The North American region has emerged as a dominant player in the invasive fungal infections market, owing to several key factors. Firstly, the region has witnessed a rise in the number of cases of mucormycosis, along with the presence of major industry players, and the development of the healthcare sector. Additionally, the availability of new anti-fungal drugs in the region has further contributed to its growth. Moreover, the increase in the aged population with a high incidence of fungal conditions, coupled with high awareness among the population pertaining to preventive and restorative treatments, has also propelled the market forward.

Asia Pacific is expected to register the highest CAGR during the forecasted period, owing to surge in prevalence of mucormycosis fungal infection that is caused by chronic disease. Inflationary income levels and rising life expectancy are the main market drivers. Additionally, as older adults are more prone to oral diseases, the region's geriatric population growth is driving up demand for invasive fungal infections. Moreover, the governments of numerous nations in the region are launching programs to offer patients coverage for invasive fungal infections, which is having a positive impact on the market.

Market Dynamics:

Growth Drivers: One of the most important factors impacting the global invasive fungal infections market is the increasing invasive fungal infections with life-threatening conditions. There are hundreds of thousands of fungus species, roughly a hundred of which can infect people, but only a few are fatal. In terms of incidence and general prevalence, emerging countries are particularly hard hit. These infections can be severe and potentially fatal, particularly in individuals with weakened immune systems, such as those with cancer, HIV/AIDS, organ transplant recipients, and patients receiving immunosuppressive therapies. They can cause severe damage to organs such as lungs, brain, liver, and blood vessels, leading to organ failure and death if not promptly diagnosed and treated. This underscores the urgent need for effective antifungal therapies to combat these life-threatening infections, thus driving the market growth. Furthermore, the market has been growing over the past few years, due to factors such as rapid urbanization, aging population, increasing healthcare expenditure, increasing government support, advancements in antifungal drug development and changing lifestyles and environmental factor.

Challenges: However, the market has been confronted with some challenges specifically, high adverse effects, usage of conventional drugs and complex and evolving fungal pathogens, etc. Invasive fungal infections are serious infections caused by fungi that penetrate deep into the body, often affecting people with weakened immune systems. Conventional drugs, such as antifungal medications, are often used to treat these infections. However, the high adverse effects and overuse of these drugs present a challenge to the invasive fungal infection market. For example, amphotericin B, which is widely recommended for fungal infections, has a number of side effects. These include nephrotoxicity, hypokalemia, bone marrow suppression, and others, all of which have a detrimental impact on market growth.

Trends: The market is projected to grow at a fast pace during the forecast period, due to use of AI in vaccine and drug design, increase in R&D activities, advancements in diagnostic techniques and increase in usage of nanotechnology in formulation of advanced antifungal drugs. The global rise in the occurrence of fungal infections has driven producers to create enhanced formulation drugs for better clinical outcomes. This, in turn, is fuelling market expansion throughout the predicted period. As a result, producers are focused on new drug formulations that can be manufactured utilizing nanotechnology. Nanotechnology, for example, is used to treat onychomycosis (nail fungus), which causes nail deformity, discomfort, and other problems. Furthermore, manufacturers are focusing on the development of medications such as Amphotericin B, a topical nanoemulsion formulation Antifungal agent for the treatment of candidiasis and aspergillosis, which is causing the market to rise.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic has had a significant negative impact on the market for invasive fungal infections. As the healthcare system has been overwhelmed with managing the pandemic, resources and attention have been largely diverted towards addressing COVID-19, resulting in decreased focus on other medical conditions, including invasive fungal infections. One of the main challenges has been the disruption of routine medical services, including elective surgeries and diagnostic procedures, due to lockdowns, social distancing measures, and prioritization of COVID-19 patients. As a result, there has been a reduction in the number of invasive procedures and diagnostic tests, leading to decreased detection and management of invasive fungal infections.

Despite the challenges posed by the COVID-19 pandemic, the invasive fungal infections market is expected to continue its growth trajectory in the coming years. The COVID-19 pandemic has raised awareness about the risks of invasive fungal infections, particularly in patients with weakened immune systems due to COVID-19, prolonged hospitalization, and use of immunosuppressive medications. As a result, there may be an increased focus on early diagnosis and management of invasive fungal infections in post-COVID times, leading to an expansion of the invasive fungal infections market.

Competitive Landscape:

Over 72 medicines have been approved for the treatment of various types of invasive fungal infections. The majority target a wide range of fungal infections and are frequently used in tandem. Because of the early discoveries of the different classes of molecules, the original medications' patents have expired. As a result, the market is fragmented, with both generic and enhanced versions based on the same parent molecule. Key players are vying for market share through the development and commercialization of innovative antifungal drugs.

The key players in the global invasive fungal infections market are:

GlaxoSmithKline

Merck & Co., Inc.

Pfizer Inc.

Cidara Therapeutics, Inc.

Astellas Pharma Inc.

Gilead Sciences, Inc.

Novo Nordisk A/S (Xellia Pharmaceuticals)

Biosergen AB

Matinas BioPharma Holdings, Inc.

Pulmocide Ltd.

F2G Ltd.

Among the best-selling drugs is the liposomal version of amphotericin B from Gilead /Astellas Pharma. The two pharmaceutical giants, Pfizer and Merck & Co, have drugs in commercial Phase from the azole class of molecules. The most notable are Posaconazole and Voriconazole. There ar several number of candidates which are under development phase. Most of the projects under development are small molecules and further related to the azoles, echi-nocandins, and several generic candidates. However, there are also antibody molecules in early preclinical development, which are currently not on the market. 

Table of Contents

1. Executive Summary

2. Introduction

• 2.1 Invasive Fungal Infections: An Overview
  • 2.1.1 Definition of Invasive Fungal Infections
• 2.2 Invasive Fungal Infections Segmentation: An Overview
  • 2.2.1 Invasive Fungal Infections Segmentation

3. Global Market Analysis

• 3.1 Global Invasive Fungal Infections Market: An Analysis
  • 3.1.1 Global Invasive Fungal Infections Market: An Overview
  • 3.1.2 Global Invasive Fungal Infections Market by Value
  • 3.1.3 Global Invasive Fungal Infections Market by Molecule Class (Azoles, Echinocandins, Allylamines/Pyrimidines, Polyenes and Others)
  • 3.1.4 Global Invasive Fungal Infections Market by Infection Type (Candidiasis, Aspergillosis, Cryptococcus, and Other)
  • 3.1.5 Global Invasive Fungal Infections Market by Region (North America, Europe, Asia Pacific and Rest of the World)
• 3.2 Global Invasive Fungal Infections Market: Molecule Class Analysis
  • 3.2.1 Global Invasive Fungal Infections Market by Molecule Class: An Overview
  • 3.2.2 Global Azoles Invasive Fungal Infections Market by Value
  • 3.2.3 Global Echinocandins Invasive Fungal Infections Market by Value
  • 3.2.4 Global Allylamines/Pyrimidines Invasive Fungal Infections Market by Value
  • 3.2.5 Global Polyenes Invasive Fungal Infections Market by Value
  • 3.2.6 Global Other Invasive Fungal Infections Molecule Class Market by Value
• 3.3 Global Invasive Fungal Infections Market: Infection Type Analysis
  • 3.3.1 Global Invasive Fungal Infections Market by Infection Type: An Overview
  • 3.3.2 Global Invasive Candidiasis Fungal Infections Market by Value
  • 3.3.3 Global Invasive Aspergillosis Fungal Infections Market by Value
  • 3.3.4 Global Invasive Cryptococcus Fungal Infections Market by Value
  • 3.3.5 Global Other Invasive Fungal Infections Market by Value

4. Regional Market Analysis

• 4.1 North America Invasive Fungal Infections Market: An Analysis
  • 4.1.1 North America Invasive Fungal Infections Market: An Overview
  • 4.1.2 North America Invasive Fungal Infections Market by Value
  • 4.1.3 North America Invasive Fungal Infections Market by Region (The US, Canada, and Mexico)
  • 4.1.4 The US Invasive Fungal Infections Market by Value
  • 4.1.5 Canada Invasive Fungal Infections Market by Value
  • 4.1.6 Mexico Invasive Fungal Infections Market by Value
• 4.2 Europe Invasive Fungal Infections Market: An Analysis
  • 4.2.1 Europe Invasive Fungal Infections Market: An Overview
  • 4.2.2 Europe Invasive Fungal Infections Market by Value
  • 4.2.3 Europe Invasive Fungal Infections Market by Region (Germany, UK, France, Italy, Spain, and Rest of Europe)
  • 4.2.4 Germany Invasive Fungal Infections Market by Value
  • 4.2.5 United Kingdom Invasive Fungal Infections Market by Value
  • 4.2.6 France Invasive Fungal Infections Market by Value
  • 4.2.7 Italy Invasive Fungal Infections Market by Value
  • 4.2.8 Spain Invasive Fungal Infections Market by Value
  • 4.2.9 Rest of Europe Invasive Fungal Infections Market by Value
• 4.3 Asia Pacific Invasive Fungal Infections Market: An Analysis
  • 4.3.1 Asia Pacific Invasive Fungal Infections Market: An Overview
  • 4.3.2 Asia Pacific Invasive Fungal Infections Market by Value
  • 4.3.3 Asia Pacific Invasive Fungal Infections Market by Region (China, Japan, India, and Rest of the Asia Pacific)
  • 4.3.4 China Invasive Fungal Infections Market by Value
  • 4.3.5 Japan Invasive Fungal Infections Market by Value
  • 4.3.6 India Invasive Fungal Infections Market by Value
  • 4.3.7 Rest of Asia Pacific Invasive Fungal Infections Market by Value
• 4.4 Rest of the World Invasive Fungal Infections Market: An Analysis
  • 4.4.1 Rest of the World Invasive Fungal Infections Market: An Overview
  • 4.4.2 Rest of the World Invasive Fungal Infections Market by Value

5. Impact of COVID-19

5.1. Impact of COVID-19 on Invasive Fungal Infections Market

• 5.2 Post COVID Scenario

6. Market Dynamics

• 6.1 Growth Drivers
  • 6.1.1 Increasing Invasive Fungal Infections with Life-threatening Conditions
  • 6.1.2 Rapid Urbanization
  • 6.1.3 Aging Population
  • 6.1.4 Increasing Healthcare Expenditure
  • 6.1.5 Increasing Government Support
  • 6.1.6 Advancements in Antifungal Drug Development
  • 6.1.7 Changing Lifestyles and Environmental Factor
• 6.2 Challenges
  • 6.2.1 High Adverse Effects and Usage of Conventional Drugs
  • 6.2.2 Complex and Evolving Fungal Pathogens
• 6.3 Market Trends
  • 6.3.1 Use of AI in Vaccine and Drug Design
  • 6.3.2 Increase in R&D Activities
  • 6.3.3 Advancements in Diagnostic Techniques
  • 6.3.4 Increase in Usage of Nanotechnology in Formulation of Advanced Antifungal Drugs

7. Competitive Landscape

• 7.1 Global Invasive Fungal Infections Players by Market Share
• 7.2 Global Invasive Fungal Infections Market Players: Key Comparison
• 7.3 Global Invasive Fungal Infections Market Players: Products Pipeline

8. Company Profiles

• 8.1 GlaxoSmithKline Plc
  • 8.1.1 Business Overview
  • 8.1.2 Sales by Products
  • 8.1.3 Business Strategies
• 8.2 Merck & Co., Inc.
  • 8.2.1 Business Overview
  • 8.2.2 Operating Segments
  • 8.2.3 Business Strategies
• 8.3 Pfizer Inc.
  • 8.3.1 Business Overview
  • 8.3.2 Operating Segments
  • 8.3.3 Business Strategies
• 8.4 Cidara Therapeutics, Inc.
  • 8.4.1 Business Overview
  • 8.4.2 Revenue from Collaboration and License Agreement
  • 8.4.3 Business Strategies
• 8.5 Astellas Pharma Inc.
  • 8.5.1 Business Overview
  • 8.5.2 Sales by Region
  • 8.5.3 Business Strategy
• 8.6 Gilead Sciences, Inc.
  • 8.6.1 Business Overview
  • 8.6.2 Sales by Product
  • 8.6.3 Business Strategies
• 8.7 Novo Nordisk A/S (Xellia Pharmaceuticals)
  • 8.7.1 Business Overview
  • 8.7.2 Operating Segments
  • 8.7.3 Business Strategy
• 8.8 Biosergen AB
  • 8.8.1 Business Overview
  • 8.8.2 Business Strategies
• 8.9 Matinas BioPharma Holdings, Inc.
  • 8.9.1 Business Overview
  • 8.9.2 Business Strategies
• 8.10 Pulmocide Ltd.
  • 8.10.1 Business Overview
  • 8.10.2 Business Strategies
• 8.11 F2G Ltd.
  • 8.11.1 Business Overview
  • 8.11.2 Business Strategies

List of Tables

• Table 1: Global Invasive Fungal Infections Market Players: Key Comparison
• Table 2: Global Invasive Fungal Infections Market Players: Products Pipeline

List of Figures

• Figure 1: Common Types of Invasive Fungal Infections
• Figure 2: Invasive Fungal Infections Segmentation
• Figure 3: Global Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 4: Global Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 5: Global Invasive Fungal Infections Market by Molecule Class; 2022 (Percentage, %)
• Figure 6: Global Invasive Fungal Infections Market by Infection Type; 2022 (Percentage, %)
• Figure 7: Global Invasive Fungal Infections Market by Region; 2022 (Percentage, %)
• Figure 8: Global Azoles Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 9: Global Azoles Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 10: Global Echinocandins Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 11: Global Echinocandins Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 12: Global Allylamines/Pyrimidines Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 13: Global Allylamines/Pyrimidines Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 14: Global Polyenes Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 15: Global Polyenes Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 16: Global Other Invasive Fungal Infections Molecule Class Market by Value; 2018-2022 (US$ Million)
• Figure 17: Global Other Invasive Fungal Infections Molecule Class Market by Value; 2023-2028 (US$ Million)
• Figure 18: Global Invasive Candidiasis Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 19: Global Invasive Candidiasis Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 20: Global Invasive Aspergillosis Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 21: Global Invasive Aspergillosis Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 22: Global Invasive Cryptococcus Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 23: Global Invasive Cryptococcus Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 24: Global Other Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 25: Global Other Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 26: North America Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 27: North America Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 28: North America Invasive Fungal Infections Market by Region; 2022 (Percentage, %)
• Figure 29: The US Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 30: The US Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 31: Canada Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 32: Canada Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 33: Mexico Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 34: Mexico Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 35: Europe Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 36: Europe Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 37: Europe Invasive Fungal Infections Market by Region; 2022 (Percentage, %)
• Figure 38: Germany Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 39: Germany Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 40: United Kingdom Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 41: United Kingdom Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 42: France Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 43: France Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 44: Italy Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 45: Italy Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 46: Spain Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 47: Spain Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 48: Rest of Europe Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 49: Rest of Europe Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 50: Asia Pacific Invasive Fungal Infections Market by Value; 2018-2022 (US$ Billion)
• Figure 51: Asia Pacific Invasive Fungal Infections Market by Value; 2023-2028 (US$ Billion)
• Figure 52: Asia Pacific Invasive Fungal Infections Market by Region; 2022 (Percentage, %)
• Figure 53: China Invasive Fungal Infections Market by Value, 2018-2022 (US$ Million)
• Figure 54: China Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 55: Japan Invasive Fungal Infections Market by Value, 2018-2022 (US$ Million)
• Figure 56: Japan Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 57: India Invasive Fungal Infections Market by Value, 2018-2022 (US$ Million)
• Figure 58: India Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 59: Rest of Asia Pacific Invasive Fungal Infections Market by Value, 2018-2022 (US$ Million)
• Figure 60: Rest of Asia Pacific Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 61: Rest of the World Invasive Fungal Infections Market by Value; 2018-2022 (US$ Million)
• Figure 62: Rest of the World Invasive Fungal Infections Market by Value; 2023-2028 (US$ Million)
• Figure 63: Expected Prevalence of Invasive Fungal Infections in The US, European Union, UK, Japan & India, 2034 (Thousand)
• Figure 64: Global Urban Population as a Share of Total Population; 2016, 2021 & 2050 (Percentage, %)
• Figure 65: Global Percentage Of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
• Figure 66: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
• Figure 67: Global Market Size for Artificial Intelligence in Healthcare; 2021-2030 (US$ Billion)
• Figure 68: Global Invasive Fungal Infections Players by Market Share; 2022 (Percentage, %)
• Figure 69: GlaxoSmithKline Plc Sales by Products; 2022 (Percentage, )
• Figure 70: Merck & Co., Inc. Sales by Segments; 2022 (Percentage, %)
• Figure 71: Pfizer Inc. Revenue by Segment; 2022 (Percentage,%)
• Figure 72: Cidara Therapeutics, Inc. Revenue from Collaboration and License Agreements; 2022 (Percentage, %)
• Figure 73: Astellas Pharma Inc. Sales by Region; 2022 (Percentage, %)
• Figure 74: Gilead Sciences, Inc. Sales by Product; 2022 (Percentage, %)
• Figure 75: Novo Nordisk A/S Net Sales by Segment; 2022 (Percentage, %)